SCHEMBL2748839

SCHEMBL2748839

CNC(=O)c1cc(Oc2ccc3c(C(=O)Nc4cccc(C)c4)cccc3c2)ccn1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.76
FGFR1 P11362 2/20 0.53
AURKA O14965 2/20 0.52
LCK P06239 2/20 0.52
RET P07949 2/20 0.52
AURKB Q96GD4 2/20 0.52
PLK4 O00444 1/20 0.52
MAPK13 O15264 1/20 0.52
JAK2 O60674 1/20 0.52
MAP4K4 O95819 1/20 0.52
ABL1 P00519 1/20 0.52
FYN P06241 1/20 0.52
LYN P07948 1/20 0.52
ROS1 P08922 1/20 0.52
SRC P12931 1/20 0.52
RPS6KB1 P23443 1/20 0.52
EPHA2 P29317 1/20 0.52
TYK2 P29597 1/20 0.52
AXL P30530 1/20 0.52
FRK P42685 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2747166 0.93 KDR (0.78) KDRFGFR1AURKALCKAURKB
SCHEMBL2748756 0.91 KDR (0.84) KDRFGFR1AURKALCKRET
SCHEMBL2746993 0.91 KDR (0.84) KDRFGFR1RETMETBRAF
SCHEMBL4548907 0.90 KDR (0.62) KDRRETPDGFRBKITFLT1
SCHEMBL2748448 0.90 KDR (0.75) KDRFGFR1AURKALCKRET
SCHEMBL2747497 0.90 KDR (0.75) KDRFGFR1AURKALCKAURKB
SCHEMBL2747739 0.90 KDR (0.84) KDRFGFR1AURKALCKRET
SCHEMBL2746247 0.88 KDR (0.73) KDRFGFR1AURKALCKRET
SCHEMBL2747180 0.88 KDR (0.73) KDRFGFR1AURKALCKRET
SCHEMBL2748188 0.88 KDR (0.81) KDRFGFR1AURKALCKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885FGFR1 9/4885AURKA 4148/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885FGFR1 9/4885AURKA 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.